Breyanzi – Talk Bio

Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition

5 months ago talkbio0Tagged Allogene, Breyanzi, CAR-T, cema-cel, Clinical Trials, leukemia, Myers, squibb

Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma

11 months ago talkbio0Tagged Approved, Breyanzi, Cancer Therapeutic Procedure, CAR-T, Immunotherapy, Lymphoma, Follicular, Myers, United States Food and Drug Administration

Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.

Bristol Myers’ Breyanzi Approved by FDA for Follicular Lymphoma, Joining Gilead and Novartis in CAR-T Treatment

11 months ago talkbio0Tagged Breyanzi, Cancer Therapeutic Procedure, CAR-T, Gilead, Immunotherapy, Lymphoma, Follicular, Myers, Novartis, United States Food and Drug Administration

Bristol Myers, Breyanzi, FDA, follicular lymphoma, CAR-T, Gilead, Novartis, cancer treatment, immunotherapy